Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin Carcinogenicity Data Central To Protracted Review - GAO

Executive Summary

FDA revisited Claritin animal carcinogenicity data and its relevance to humans two and a half years into its review of the Schering-Plough antihistamine following an agency restructuring, the General Accounting Office said in an Aug. 10 report.

You may also be interested in...



SmithKline Relafen Patent Ruling Clears Way For Trial In 2001

Patent infringement litigation between SmithKline Beecham and generic companies seeking to launch versions of Relafen (nabumetone) will likely go to trial in the first half of 2001, the company said following an Aug. 16 summary judgment ruling.

SmithKline Relafen Patent Ruling Clears Way For Trial In 2001

Patent infringement litigation between SmithKline Beecham and generic companies seeking to launch versions of Relafen (nabumetone) will likely go to trial in the first half of 2001, the company said following an Aug. 16 summary judgment ruling.

Claritin Extension Should Be Debated As Product-Specific Bill - Barr CEO

The merits of a patent extension for Schering-Plough's Claritin should be debated in the context of a specific bill for that purpose, Barr CEO Bruce Downey contended at a House Judiciary/Courts & Intellectual Property Subcommittee hearing May 21.

Related Content

UsernamePublicRestriction

Register

PS036487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel